-
10m 5sPart 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
7m 43s
-
6m 35sPart 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
5m 6sPart 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
3m 53sPart 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
4m 31sPart 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
6m 37sPart 4 | Session 13 Pooled MACE Data for Obicetrapib
-
8m 9sPart 4 | Session 14 STRIDE: Outcomes by Sex
-
4m 27sPart 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
7m 20sPart 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
3m 38sPart 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
-
47m 54sPart 1 | Session 1 View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
-
36m 33sPart 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
-
11m 8sPart 2 | Session 1 Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
19m 8sPart 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 11sPart 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
14m 10sPart 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 4sPart 3 | Session 1 VICTOR: Vericiguat in Heart Failure
-
12m 24sPart 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
-
12m 36sPart 3 | Session 3 BETAMI-DANBLOCK: Beta-blockers after MI
-
14m 3sPart 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
14m 30sPart 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
27m 8s
-
4m 15sPart 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
3m 52sPart 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
5m 10s
-
7m 42sPart 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
7m 12s
ESC Congress 2025 - Exploratory findings from STEEER-AF suggest that a comprehensive educational programme for stroke prevention and rhythm control therapy improved outcomes for patients with atrial fibrillation.
Dr Dipak Kotecha (University of Birmingham, Birmingham, UK) joins us to discuss findings from the STEEER-AF (NCT04396418) cluster randomised trial by the ESC and EHRA. The prospective, international, controlled trial aimed to investigate the effect of a comprehensive educational programme for healthcare professionals on stroke prevention and rhythm control therapy in patients with AF. Patients from centres across six European countries were randomised to either a structured education programme or no additional education.
Findings showed that in the stroke prevention group, of those who were fully guideline adherent, patients were significantly less likely to have the composite clinical outcome, which included mortality, stroke and transient ischemic attack. In this group, there was a 33% reduction in adverse events, if guideline adherent. This did not occur in the rhythm control analysis, though there were some groups with prognostic improvement.
Interview Questions:
- What is the background behind the STEEER-AF trial?
- Could you tell us about the comprehensive educational programme?
- What was the study design and patient population?
- What were the key findings?
- What are the take-home messages for practice
- What further research is needed in this area, and what are the next steps?
Recorded on-site at ESC Congress 2025, Madrid.
Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Arrhythmia Academy.
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Dipak Kotecha
Professor of Cardiology & Cardiac Imaging and Consultant Cardiologist
Dipak Kotecha is a Professor of Cardiology at the University of Birmingham, and a Consultant Cardiologist specialising in cardiac imaging. He has completed a prestigious National Institute for Health Research (NIHR) Fellowship and was awarded the British Cardiovascular Society, Michael Davies Medal, in 2018 for his contribution to cardiovascular medicine. He works extensively across the European Society of Cardiology (ESC) in education, trials and guidelines, and his research focuses on the interaction of heart failure and atrial fibrillation, supported by grants from the NIHR, British Heart Foundation and the European Union. Dipak leads international collaborations, with interests in patient involvement, big data approaches, the application of artificial intelligence, and the use of novel technology (the cardAIc group). He is passionate about innovative yet pragmatic trial design and healthcare-embedded approaches to improve patient care – this includes the…
Comments